Engineering Tissue-Specific SureTACs for Targeted Cell Surface Protein Degradation
- Developing bispecific SureTAC antibodies that drive internalization and degradation of membrane proteins in a tissue- and disease-specific manner
- Harnessing the TED-I screening platform to identify high-potency E3–target pairs for enhanced degradation efficiency
- Demonstrating translational potential with preclinical data validating selective degradation of challenging membrane targets